Related Experiment Videos
A revised role for cyclic AMP in prostaglandin-induced bone resorption
Medical Biology
|February 1, 1980
Summary
Cyclic AMP (cAMP) inhibits prostaglandin-induced bone resorption in murine calvarial bones. This effect was observed with dibutyryl cAMP and phosphodiesterase inhibitors, suggesting a potential role in regulating bone mineral release.
Area of Science:
- Bone biology
- Cell signaling
- Pharmacology
Background:
- Prostaglandins E1 and E2 (PGE1, PGE2) stimulate bone resorption.
- Cyclic AMP (cAMP) is a key intracellular second messenger.
- The interaction between cAMP and prostaglandin-mediated bone resorption requires further elucidation.
Purpose of the Study:
- To investigate the effect of cyclic AMP on prostaglandin-induced bone resorption.
- To determine if phosphodiesterase inhibitors modulate prostaglandin-stimulated bone mineral release.
Main Methods:
- Murine calvarial bones from 6-7 day-old mice were cultured for 48 hours.
- Bone resorption was assessed by measuring the release of 45Ca from prelabeled bones.
- Effects of dibutyryl cAMP, theophylline, and 3-isobutyl-methylxanthine were evaluated.
Main Results:
- Dibutyryl cAMP inhibited prostaglandin-induced 45Ca mobilization in a dose-dependent manner.
- Theophylline and 3-isobutyl-methylxanthine reduced prostaglandin-stimulated 45Ca release.
- Lower doses of phosphodiesterase inhibitors were effective in reducing stimulated vs. unstimulated resorption.
Conclusions:
- Cyclic AMP exerts an inhibitory effect on prostaglandin-induced bone resorption.
- Phosphodiesterase inhibitors can attenuate prostaglandin-mediated bone mineral release.
- The mechanism may involve cAMP's ability to inhibit prostaglandin-stimulated lysosomal enzyme release.